A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

By M. Gilbert, J. Dignam, T. Armstrong, J. Wefel, D. Blumenthal, M. Vogelbaum, H. Colman, A. Chakravarti, S. Pugh, M. Won and 12 more. New England Journal of Medicine, 2014

2,515 citations recorded by the source corpus.

BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known. METHODS In this randomized, double-blind, placebo-controlled trial, we treated adults who had centrally confirmed glioblastoma with radiotherapy (60 Gy) and daily temozolomide. Treatment with bevacizumab or placebo began during week 4 of radiotherapy and was continued for up to 12 cycles of maintenance chemotherapy. At disease progression, the assigned treatment was revealed, and bevacizumab therapy could be initiated or continued. The trial was designed to detect a 25% reduction in the risk of death and a 30% reduction in the risk of progression or death, the two coprimary end points, with the addition of bevacizumab. RESULTS A total of 978 patients were registered, and 637 underwent randomization. There was no significant difference in the duration of overall survival between the bevacizumab group and the placebo group (median, 15.7 and 16.1 months, respectively; hazard ratio for death in the bevacizumab group, 1.13). Progression-free survival was longer in the bevacizumab group (10.7 months vs. 7.3 months; hazard ratio for progression or death, 0.79). There were modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutropenia in the bevacizumab group. Over time, an increased symptom burden, a worse quality of life, and a decline in neurocognitive function were more frequent in the bevacizumab group. CONCLUSIONS First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement target.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/361fa37d7278acd2216beb93a5ee54894e765066

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015, background): “For example, 3 large phase 3 trials were completed, based on promising phase 3 data, which failed to significantly extend OS.5,6,16 These failures highlight the need to optimize the use of imaging as a surrogate tool to better understand the response to novel therapeutics.”
Artificial intelligence in Cancer Imaging: Clinical Challenges and Applications (2019, background): “131,132 Currently, there is no clinically useful molecular marker predictive of treat-ment response for antiangiogenic therapy.”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “80) , involving newly diagnosed GBM patients, PFS, but not OS, were improved with the combination of bevacizumab with radiotherapy and temozolomide compared with radiotherapy and temozolomide alone 87,88 .”
Current Challenges and Opportunities in Treating Glioblastoma (2018, background): “Out of 637 patients receiving either 10 mg/kg bevacizumab every 2 weeks or placebo, there was no significant difference in overall survival between the two groups (median overall survival of 15.7 months for bevacizumab-treated patients vs. 16.1 months for the placebo group) (Gilbert et al., 2014).”
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017, neutral): “Gastrointestinal disorders 23 (5) 8 (4)”
Federated learning enables big data for rare cancer boundary detection (2022, background): “The exact 49 site IDs are: 1, 2, 3, 4, 5, 6, 7, 9, 10, 12, 13, 14, 15, 16, 17, 18, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 45, 46, 48, 49, 50, 52, 53, 54, 56, 59, 60.”